EW
Edwards Lifesciences Corporation
September 11, 2026 · intraday
- Rarity
- 1.02
- Peak move
- −3.31%
- Float cap
- —
Edwards Lifesciences Corporation develops and sells medical technologies for structural heart disease. Its portfolio includes transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical heart valves and repair products. These therapies are used by cardiac surgeons and interventional cardiologists to treat patients with aortic, mitral, tricuspid, and pulmonic valve disease and other advanced cardiovascular conditions.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
9 events · 0 from SEC or newswire · 0 timed with the move- Key event
regulatory_approvalCMS initiated a national coverage analysis for TAVR devices treating aortic regurgitation, including Edwards' J-Valve and JenaValve, with completion expected by June 8, 2027.
analyst_ratingBTIG Research reaffirmed a Buy rating and $110 price target on Edwards Lifesciences on Sept. 11, 2026, implying roughly 26.9% upside from the $86.69 opening price.
institutional_flowEngineers Gate Manager LP cut its Edwards Lifesciences stake by 37.3% in the second quarter, selling 81,590 shares to retain 137,294 shares worth about $12.42 million, per its Form 13F filing.
insider_saleEdwards Lifesciences insiders sold 5,045 shares worth $457,749 over the prior 90 days, including SVP Andrew Dahl selling 544 shares at $91.06 on August 31, leaving him 14,868 shares, and VP Annette Brüls selling 2,644 shares at $89.98 on August 28.
analyst_ratingCanaccord reiterated a Hold rating and $85.00 price target on Edwards Lifesciences following the CMS TAVR Medicare coverage decision.
analyst_ratingStifel analysts called CMS's final TAVR national coverage determination constructive for the TAVR market and for Edwards Lifesciences, noting TAVR is a $7B+ global market representing about 75% of Edwards' revenue.
- Key event
regulatory_approvalCMS published its final TAVR National Coverage Determination Decision Memo on Sept. 10, 2026, expanding Medicare coverage to asymptomatic severe aortic stenosis patients, removing facility-level procedural volume thresholds, and allowing the second Heart Team assessment to be a chart review or telehealth visit.
- Key event
reg_fd_disclosureEdwards Lifesciences welcomed the CMS TAVR coverage decision and reaffirmed its previously communicated 2026 guidance of 10%-11% sales growth and EPS of $2.95-$3.05, saying adoption will take time and that 2027 guidance is due at its December investor conference.
analyst_ratingWilliam Blair analyst Brandon Vazquez maintained a Buy rating on Edwards Lifesciences, saying the CMS TAVR coverage expansion to asymptomatic severe aortic stenosis could enlarge the addressable market by roughly 30%.